Trinity Biotech Plc · NASDAQ:TRIB
Trinity Biotech — FY2025 Earnings Presentation
20 slides from Trinity Biotech's earnings presentation, Oct 15, 2026
Slide 1: Financial Results for Quarter and Year Ended December 31, 2025
Financial Results For Quarter Ended December 31, 2025 (unaudited), and Year Ended December 31, 2025
Slide 2: Q4 2025 Financial Results - Summary
Q4 2025 Financial Results - Summary Overview • Revenue for the quarter ended as of 31 December 2025 on a like-for-like basis (excluding sub-scale lower- margin third-party product lines) was $11.0m vs Q4, 2024 $15.1m. • The Company experienced a decline in quarter-on-quarter revenues in Q4, 2025, dr
Slide 3: Q4 2025 Revenue & Gross Profit
Q4 2025 Revenue & Gross Profit Revenue Overview • Total revenue of $11.1m, broadly in line with previous guidance, compared to $15.9m in Q4, 2024. • Like-for-like revenue (excluding sub-scale lower-margin third-party product lines being discontinued): Q4 2025: $11.0m vs Q4, 2024: $15.1m. • The main
Slide 4: Q4 2025 Cost Base & Liquidity
Q4 2025 Cost Base & Liquidity • R&D expense: (Q4, 2025: $1.1m vs Q4 2024: $1.5m), with $1.7m capitalised including $1.2m for CGM programme. • SG&A expense: (Q4, 2025: $6.0m vs Q4, 2024: $8.4m) with decrease driven primarily by cost reductions associated with the Comprehensive Transformation Plan. •
Slide 5: Financial Results For Year Ended December 31, 2025
Financial Results For Year Ended December 31, 2025
Slide 6: FY2025 Financial Results - Summary
FY2025 Financial Results - Summary Overview • Revenues for the year ended 31 December 2025 on a like-for-like basis (excluding sub-scale lower-margin third-party product lines) were $43.3m compared to $58.8m for 2024. • The year-on-year decline in revenues in 2025 was mainly driven by reductions in
Slide 7: FY2025 Revenue & Gross Profit
FY2025 Revenue & Gross Profit Revenue Overview • Total revenue: $43.8m, compared to $61.6m in 2024. • Like-for-like revenue (excluding sub-scale lower-margin third-party product lines being discontinued): 2025: $43.3m vs 2024: $58.8m. • Main movements in revenues, on like-for-like basis, were: • Rap
Slide 8: FY2025 Cost Base & Liquidity
FY2025 Cost Base & Liquidity • R&D expense: (2025: $3.6m vs 2024: $4.5m), with $9.2m capitalised including $7.3m for CGM programme. • SG&A expense: (2025: $24.7m vs 2024: $28.8m) with decrease driven primarily by cost reductions from the Comprehensive Transformation Plan, including organisational re
Slide 9: Supporting Schedules
Supporting Schedules For Quarter Ended and Year Ended December 31, 2025
Slide 10: Net Financing Expense
Net Financing Expense Three Months Ended Year Ended (US$’000’s) December 31, December 31, (unaudited) 2025 2024 2025 2024 Term Loan interest 3,721 3,900 14,048 12,733 Convertible note interest 314 296 1,228 1,159 Notional interest on lease liabilities for Right-of-use assets 165 144 644 592 Fair val
Slide 11: EBITDA & Adjusted EBITDA Reconciliation
EBITDA & Adjusted EBITDA Reconciliation Three Months Ended Twelve Months Ended (US$’000’s) December 31, December 31, (unaudited) 2025 2024 2025 2024 Loss for the period on continuing operations (17,476) (16,382) (37,376) (31,216) Income tax expense/ (credit) (174) 585 199 486 Net financing expense 1
Slide 12: Use of Non-IFRS Financial Measures
Use of Non-IFRS Financial Measures The accompanying summary unaudited financial statements were prepared in accordance with International Financial Reporting Standards (IFRS). To supplement the consolidated financial statements presented in accordance with IFRS, the Company presents non-IFRS present
Slide 13: Forward-Looking Statements
Forward-Looking Statements This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resour
Slide 14: About Trinity Biotech
About Trinity Biotech Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. Our current products are used to detect a variety of health conditions including autoimmune, infectious and sexually transm
Slide 15: Consolidated Statement of Operations
Trinity Biotech PLC Consolidated Statement of Operations (US$000’s except share and per data) Three Months Ended December 31, Twelve Months Ended December 31, (unaudited) 2025 2024 2025 2024 Revenues 11,072 15,857 43,785 61,555 Cost of sales (7,174) (10,980) (26,898) (40,114) Gross profit 3,898 4,87
Slide 16: Consolidated Balance Sheets
Trinity Biotech PLC Consolidated Balance Sheets (US$000’s) December 31, September 30, June 30, March 31, December 31, 2025 2025 2025 2025 2024 (audited) (unaudited) (unaudited) (unaudited) (audited) ASSETS Non-current assets Property, plant and equipment 5,302 4,011 4,309 4,382 4,621 Goodwill and in
Slide 17: Consolidated Balance Sheets - continued
Trinity Biotech PLC Consolidated Balance Sheets - continued (US$000’s) December 31, September 30, June 30, March 31, December 31, 2025 2025 2025 2025 2024 (audited) (unaudited) (unaudited) (unaudited) (audited) EQUITY AND LIABILITIES - continued Current liabilities Senior secured term loan 108,015 -
Slide 18: Consolidated Statement of Cash Flows
Trinity Biotech PLC Consolidated Statement of Cash Flows (US$000’s) Three Months Ended December 31, Twelve Months Ended December 31, (unaudited) 2025 2024 2025 2024 Cash flows from operating activities Loss for the period (17,476) (16,955) (37,376) (31,789) Adjustments to reconcile loss to cash used
Slide 19: Consolidated Statement of Cash Flows
Trinity Biotech PLC Consolidated Statement of Cash Flows (US$000’s) Three Months Ended December 31, Twelve Months Ended December 31, (unaudited) 2025 2024 2025 2024 Cash flows from financing activities Issue of ordinary share capital incl share premium (net of issuance costs) - 545 547 7,391 Net pro
Slide 20: Investor Queries
Investor Queries Trinity Biotech Plc RedChip Companies Inc Paul Murphy David Gentry (353)-1-2769800 (1)-407-644-4256 [email protected] [email protected]